Song Kaiyang, Vijjhalwar Rohit, Aye Mo, Comninos Alexander N, Schini Marian, Abbas Afroze, Gittoes Neil, Javaid Muhammad Kassim
Medical Sciences Division, University of Oxford, Oxford OX3 9DU, UK.
Centre for Metabolic Bone Diseases, Hull Royal Infirmary, Hull HU3 2JZ, UK.
J Endocr Soc. 2025 Jan 28;9(2):bvae225. doi: 10.1210/jendso/bvae225. eCollection 2025 Jan 6.
To describe diagnostic approaches and management strategies for patients with primary hyperparathyroidism (PHPT) and recent fracture in England.
We developed a survey based on a patient at high fracture risk and a new diagnosis of probable PHPT. The survey was circulated among 50 secondary care professionals identified by the Society for Endocrinology Calcium and Bone special interest group. Descriptive statistics, combinatorial, and thematic analyses were employed.
In the patient with hyperparathyroidism and a recent fracture, 54% of respondents favoured a 24-hour urinary calcium: creatinine clearance ratio, with 85% opting to do so after correcting vitamin D levels. Thirty-two percent (16/50) preferred the spot urinary calcium:creatinine clearance ratio, as a random test (56%, n = 9/16). Ninety-six percent of the respondents agreed they would include a fracture risk assessment in their management plan. Eighty-five percent of the respondents selected dual-energy X-ray absorptiometry scans of the lumbar spine, total hip, and femoral neck as the most popular choice. Before initiating antiosteoporotic medications (AOMs), 94% of the respondents preferred correcting vitamin D levels with diverse regimens. IV zoledronate acid was the preferred AOM, and 58% (n = 29/50) supported cinacalcet usage if the patient was ineligible for parathyroid surgery, while 26% (n = 13/50) opposed cinacalcet use entirely. No significant correlation was found between status as an endocrinology consultant or working in a tertiary care hospital and these management preferences.
This study of National Health Service medical staff identified highly-varied clinical practices in managing PHPT in the setting of high fracture risk, highlighting the need for pragmatic guidelines and wider education.
描述英国原发性甲状旁腺功能亢进症(PHPT)合并近期骨折患者的诊断方法和管理策略。
我们基于一名骨折风险高且新诊断为可能的PHPT患者制定了一项调查。该调查在由内分泌学会钙与骨特别兴趣小组确定的50名二级医疗专业人员中进行了分发。采用了描述性统计、组合分析和主题分析。
在患有甲状旁腺功能亢进症且近期骨折的患者中,54%的受访者倾向于采用24小时尿钙:肌酐清除率,85%的受访者选择在纠正维生素D水平后进行该检查。32%(16/50)的受访者更喜欢采用随机检测的即时尿钙:肌酐清除率(56%,n = 9/16)。96%的受访者同意他们会在管理计划中纳入骨折风险评估。85%的受访者选择腰椎、全髋和股骨颈的双能X线吸收法扫描作为最受欢迎的选择。在开始使用抗骨质疏松药物(AOMs)之前,94%的受访者更喜欢采用不同方案纠正维生素D水平。静脉注射唑来膦酸是首选的AOM,58%(n = 29/50)的受访者支持在患者不符合甲状旁腺手术条件时使用西那卡塞,而26%(n = 13/50)的受访者完全反对使用西那卡塞。在内分泌科顾问身份或在三级医院工作与这些管理偏好之间未发现显著相关性。
这项针对国民健康服务医务人员的研究发现,在高骨折风险情况下管理PHPT时临床实践差异很大,凸显了制定实用指南和开展更广泛教育的必要性。